Full Product Name
ALG1 siRNA (Mouse)
Product Synonym Names
Chitobiosyldiphosphodolichol beta-mannosyltransferase; Asparagine-linked glycosylation protein 1 homolog; Beta-1.4-mannosyltransferase; GDP-Man:GlcNAc2-PP-dolichol mannosyltransferase; GDP-mannose-dolichol diphosphochitobiose mannosyltransferase
Product Gene Name
ALG1 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q921Q3
Specificity
ALG1 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse ALG1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of ALG1 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
ALG1 sirna
siRNA to inhibit ALG1 expression using RNA interference
Applications Tested/Suitable for ALG1 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for ALG1. It may not necessarily be applicable to this product.
NCBI Accession #
NP_663337.2
[Other Products]
NCBI GenBank Nucleotide #
NM_145362.2
[Other Products]
UniProt Primary Accession #
Q921Q3
[Other Products]
UniProt Secondary Accession #
Q3UKT8[Other Products]
UniProt Related Accession #
Q921Q3[Other Products]
Molecular Weight
51,445 Da
NCBI Official Full Name
chitobiosyldiphosphodolichol beta-mannosyltransferase
NCBI Official Synonym Full Names
asparagine-linked glycosylation 1 (beta-1,4-mannosyltransferase)
NCBI Official Symbol
Alg1??[Similar Products]
NCBI Official Synonym Symbols
HMT1; HMAT1
??[Similar Products]
NCBI Protein Information
chitobiosyldiphosphodolichol beta-mannosyltransferase
UniProt Protein Name
Chitobiosyldiphosphodolichol beta-mannosyltransferase
UniProt Synonym Protein Names
Asparagine-linked glycosylation protein 1 homolog; Beta-1,4-mannosyltransferase; GDP-Man:GlcNAc2-PP-dolichol mannosyltransferase; GDP-mannose-dolichol diphosphochitobiose mannosyltransferase
UniProt Gene Name
Alg1??[Similar Products]
UniProt Entry Name
ALG1_MOUSE
UniProt Comments for ALG1
ALG1: Participates in the formation of the lipid-linked precursor oligosaccharide for N-glycosylation. Involved in assembling the dolichol-pyrophosphate-GlcNAc(2)-Man(5) intermediate on the cytoplasmic surface of the ER. Defects in ALG1 are the cause of congenital disorder of glycosylation type 1K (CDG1K). CDGs are a family of severe inherited diseases caused by a defect in protein N- glycosylation. They are characterized by under-glycosylated serum proteins. These multisystem disorders present with a wide variety of clinical features, such as disorders of the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Belongs to the glycosyltransferase group 1 family. Glycosyltransferase 33 subfamily.
Protein type: EC 2.4.1.142; Endoplasmic reticulum; Transferase; Glycan Metabolism - N-glycan biosynthesis; Membrane protein, integral
Cellular Component: membrane; endoplasmic reticulum; integral to membrane
Molecular Function: transferase activity; transferase activity, transferring glycosyl groups; mannosyltransferase activity; chitobiosyldiphosphodolichol beta-mannosyltransferase activity
Biological Process: protein amino acid glycosylation
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
